Comparative Pharmacology
Head-to-head clinical analysis: LESCOL XL versus PRAVACHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESCOL XL versus PRAVACHOL.
LESCOL XL vs PRAVACHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased LDL receptor expression and reduced plasma LDL-cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
80 mg orally once daily, at least 4 hours after a meal. The extended-release formulation (LESCOL XL) is not interchangeable with immediate-release fluvastatin.
10-80 mg orally once daily, with or without food, typically in the evening.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3 to 2.5 hours for fluvastatin; clinical context: due to extended-release formulation, trough levels remain sufficient for once-daily dosing.
The terminal elimination half-life of pravastatin is approximately 1.8 hours, but clinical LDL-cholesterol lowering effects persist beyond this due to sustained HMG-CoA reductase inhibition.
Primarily hepatic metabolism with biliary/fecal elimination (approximately 90%); renal excretion accounts for approximately 10% of the dose.
Approximately 70% of an oral dose is excreted in feces, primarily as metabolites, with about 20% recovered in urine. Biliary excretion is a major route for parent drug and metabolites.
Category C
Category C
HMG-CoA Reductase Inhibitor
HMG-CoA Reductase Inhibitor